Last reviewed 2026-04-22 · How we verify

Bifonazole cream 1%

Bifonazole inhibits fungal cell membrane synthesis by disrupting ergosterol production through inhibition of lanosterol 14α-demethylase.

Bifonazole inhibits fungal cell membrane synthesis by disrupting ergosterol production through inhibition of lanosterol 14α-demethylase. Used for Fungal skin infections (dermatophytosis, candidiasis, pityriasis versicolor), Topical treatment of tinea pedis, tinea corporis, and tinea cruris.

At a glance

Mechanism of action

As an imidazole antifungal agent, bifonazole works by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in the fungal sterol synthesis pathway. This disruption leads to depletion of ergosterol, a critical component of the fungal cell membrane, causing membrane instability and ultimately fungal cell death. The topical cream formulation allows direct application to affected skin areas.

Approved indications

• Fungal skin infections (dermatophytosis, candidiasis, pityriasis versicolor)
• Topical treatment of tinea pedis, tinea corporis, and tinea cruris

Common side effects

• Local irritation or burning at application site
• Pruritus
• Erythema
• Contact dermatitis

Key clinical trials

• Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% (PHASE4)
• Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bifonazole cream 1% CI brief — competitive landscape report
• Bifonazole cream 1% updates RSS · CI watch RSS
• Bayer portfolio CI